For last week’s practice question, we quizzed test takers on how Metformin impacts cancer risk. 64% of respondents chose the best answer. We want to clarify and share this important information, so you can pass it on to people living with diabetes and your colleagues, plus prepare for exam success!

Before we start though, if you don’t want any spoilers and haven’t tried the question yet, you can answer it below: Answer Question

Question:

JR is taking Metformin 1000mg BID but is worried that it may increase their risk of cancer and is thinking about stopping the metformin. 

Which of the following is an accurate statement regarding metformin, cancer and safety?

Answer Choices:

1. There is research suggesting that metformin may be associated with a decreased risk of certain cancers.
2. People with diabetes have a slightly lower risk of liver and uterine cancers
3. Some brands of metformin were recalled because of an NDMA impurity, so it is best to avoid metformin for now.
4. Metformin does not increase the risk of cancer, but it can negatively impact renal function.

---

Getting to the Best Answer

Answer 1 is correct. 64.40% chose this answer, “There is research suggesting that metformin may be associated with a decreased risk of certain cancers.” YES, this is the best answer, GREAT JOB. Research is showing that metformin decreases risk of DNA replication disruption, improves cellular health and increases telomere length. In addition, it enhances intestinal microbial diversity, decreases inflammation and lowers glucose levels. There are many research studies investigating metformin’s potential for cancer prevention and improvement of treatment outcomes.

Answer 2 is incorrect. 3.17% of you chose this answer, “People with diabetes have a slightly lower risk of liver and uterine cancers.” People with diabetes are actually at higher risk for liver, pancreas and breast cancer. Researchers aren’t sure exactly why, but insulin resistance, extra body weight, and DNA replication disruption in addition to genetics and social determinants of health, all seem to play a part.

Answer 3 is incorrect. 4.52.% of respondents chose this answer, “Some brands of metformin were recalled because of an NDMA impurity, so it is best to avoid metformin for now.” Since the NDMA impurity was recognized, manufacturing processes were improved to prevent future contamination. Metformin is an important treatment option for people living with diabetes.

Finally, Answer 4 is incorrect. 27.90% chose this answer, “Metformin does not increase the risk of cancer, but it can negatively impact renal function.” Metformin does NOT harm the kidneys. As a matter of fact, metformin protects the kidneys by lowering blood sugars and decreasing inflammation. It is true that people with a GFR below 30, need to avoid metformin to prevent lactic acidosis, however this a VERY rare complication. Metformin is the most widely used diabetes medication world-wide and it has an excellent safety profile. Bonus note, metformin ER causes less GI upset and costs the same as the non-extended release version ($4 a month).

Thank you so much for reading this “Rationale of the Week”. You can download our Medication PocketCard, for more information.

---

Want to learn more about this question? Join us for our

Level 4 | Cancer and Diabetes | 1.25 CEs

Recorded & Ready for Viewing!

Diabetes Education Services Online University Courses are an excellent way to study for your exam anytime and anywhere that is convenient for you. You will have immediate access to your courses  for 1 year after your purchase date. Each individual online course includes a: video presentation, podcast, practice test and additional resources.

Patients with cancer often experience hyperglycemia secondary to treatment, which can increase risk of infection and compromise their nutritional status. In addition, recent research has identified the link between diabetes and cancer. Join us to learn more about this unexpected link and treatment strategies for steroid induced hyperglycemia using a case study approach.

Objectives:

1. Discuss the relationship between cancer, hyperglycemia and insulin resistance.
2. State 3 benefits of normalizing glucose levels during chemotherapy.
3. Using a case study approach, discuss strategies to improve glucose levels and quality of life.

Intended Audience: These courses are knowledge-based activities designed for individual or groups of diabetes educators, including RNs, RDs, Pharmacists, Nurse Practitioners, Clinical Nurse Specialists, Physician Assistants and other health care providers interested in enhancing their knowledge of diabetes management for people with cancer.

---

Don’t worry if you can’t make it live. Your registration guarantees access to the recorded version in the Online University.

All hours earned count toward your CDCES Accreditation Information

---

Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE!  Sign up below!

---

The use of DES products does not guarantee the successful passage of the CDCES exam. CBDCE does not endorse any preparatory or review materials for the CDCES exam, except for those published by CBDCE.